



Prof Concepció Soler, PhD  
Immunology Unit  
Dept Pathology and Experimental Therapeutics  
School of Medicine and Health Sciences  
University of Barcelona

Pavelló de Govern, Lab 4118  
Feixa Llarga, s/n  
08907 L'Hospitalet de Llobregat, Barcelona, Spain

January 10<sup>th</sup>, 2022

## **Postdoctoral position available** in Soler's Lab at Universitat de Barcelona

Immunology Unit, Department of Pathology and Experimental Therapy, School of Medicine and Health Sciences, Universitat de Barcelona – UB; Immunity, inflammation and Cancer Group, Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge – IDIBELL.

[Nucleases, cancer and immunity - Departament de Patologia i Terapèutica Experimental - Universitat de Barcelona \(ub.edu\); Immunity, inflammation and cancer – Idibell](#)

The research of our group is focused on decipher the mechanisms, function and dysfunction of TREX2, a keratinocyte-specific exonuclease involved in skin homeostasis, cancer and skin inflammatory diseases, such as psoriasis. In this regard, our studies have revealed TREX2 as a promising target for innovative keratinocyte-based therapies.

We are looking for a highly motivated and creative researcher interested to pursue research in skin inflammatory diseases and novel therapies.

### Candidate's requirements

- PhD degree in immunology, cellular and molecular biology or similar fields.
- Proficient in most of cellular and molecular biology, biochemistry and immunology lab techniques.
- Experience in mouse work.
- Background on gene expression and immune response, RNA-seq, isolation and culture of primary cells, analysis of immune cell subsets, among other methodologies. Also, expertise in skin models as well microbiome analysis will be highly appreciated.

### Offer

Contract of 12 months, starting next February/March 2022.

### Application

Please submit CV, academic records, motivation letter and names of referees to Dr. Concepció Soler ([concepciosoler@ub.edu](mailto:concepciosoler@ub.edu)).

Subject: Postdoctoral position\_Soler Lab

Deadline: 24<sup>th</sup> January, 2022

## Selected Publications

Parra D, Manils J, Castellana B, Viña-Vilaseca A, Morán-Salvador E, Vázquez-Villoldo N, Tarancón G, Borràs M, Sancho S, Benito C, Ortega S, **Soler C**. *Increased Susceptibility to Skin Carcinogenesis in TREX2 Knockout Mice*. Cancer Res. 2009, 69(16):6676-84.

Manils J, Gómez D, Salla-Martret M, Fischer H, Fye JM, Marzo E, Marruecos L, Serrano I, Salgado R, Rodrigo JP, Garcia-Pedrero JM, Serafin AM, Cañas X, Benito C, Toll A, Forcales SV, Perrino FW, Eckhart L, **Soler C**. *Multifaceted role of TREX2 in the skin defense against UV-induced skin carcinogenesis*. Oncotarget, 2015, 6(26):22375-96.

Manils J, Casas E, Viña-Vilaseca A, Lopez M, Díez-Villanueva A, Gómez D, Marruecos L, Ferran M, Benito C, Perrino FW, Vavouri T, de Anta JM, Ciruela F, and **Soler C**. *The exonuclease TREX2 shapes psoriatic phenotype*. J Invest Dermatol, 2016, 136(12):2345-55.

Manils J, Fischer H, Climent J, Casas E, García-Martínez C, Bas J, Vavouri T, Ciruela F, de Anta JM, Tschachler E, Eckhart L, and **Soler C**. *Double deficiency of Trex2 and Dnase1L2 nucleases leads to accumulation of DNA in lingual cornifying keratinocytes without activating inflammatory responses*. Sci Rep, 2017, 7(1):11902.

Marruecos L, Manils J, Moreta C, Gómez D, Filgaira I, Serafin A, Cañas X, Espinosa L, **Soler C**. *Single loss of a Trp53 allele triggers an increased oxidative, DNA damage and cytokine inflammatory responses through deregulation of IκBα expression*. Cell Death Dis. 2021, 12(4):359.